Upgrade to SI Premium - Free Trial

Sanofi (SNY)

48.49 0.00 (0.00%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (2/3/23)
- M&A (12/31/20 *Est)

Latest Headlines

Dupixent® (dupilumab) Approved by European Commission as the First and Only Targeted Medicine Indicated for Eosinophilic Esophagitis January 30, 2023 1:00 AM - Globe NewsWire Press Release:  Dupixent® (dupilumab) approved by European Commission as the first and only targeted medicine indicated for eosinophilic esophagitis January 30, 2023 1:00 AM - Globe NewsWire Press Release: Dupixent® (dupilumab) recommended for expanded EU approval by the CHMP to treat children as young as six months old with severe atopic dermatitis January 27, 2023 1:00 AM - Globe NewsWire Press Release: NEJM publishes once-weekly efanesoctocog alfa Phase 3 data demonstrating its potential to transform the treatment landscape for people with hemophilia A January 25, 2023 5:30 PM - Globe NewsWire Denali Therapeutics (DNLI) Announces Achievement of RIPK1 Milestone for Phase 2 Clinical Trial Initiation in Multiple Sclerosis by Sanofi January 25, 2023 8:03 AM - StreetInsider Sanofi (SAN:FP) (SNY) PT Raised to EUR90 at Barclays January 25, 2023 4:14 AM - StreetInsider Nutriband Inc. to Present at the 2023 Transdermal and Microneedle Conference January 24, 2023 6:01 AM - StreetInsider Sanofi launches first global scholarship program for students from underrepresented communities pursuing careers in healthcare January 18, 2023 7:00 AM - PR NewsWire Form 6-K Sanofi For: Jan 17 January 17, 2023 2:08 PM - SEC Filing Johnson & Johnson (JNJ) Cuts Production of Covid-19 Shot -- WSJ January 13, 2023 10:48 AM - StreetInsider Eli Lilly & Co. (LLY), Sanofi (SNY), Novo Nordisk (NVO) sued by California over insulin - Bloomberg January 12, 2023 1:51 PM - StreetInsider Citi Resumes Sanofi (SAN:FP) (SNY) at Buy January 12, 2023 4:42 AM - StreetInsider Citi Resumes Sanofi-Aventis (SNY) at Buy January 12, 2023 3:37 AM - StreetInsider Press Release: Sanofi Ventures announces multi-year capital commitment from Sanofi, increasing evergreen fund to $750M January 11, 2023 11:30 AM - Globe NewsWire Press Release: FDA accepts nirsevimab application as first protective option against RSV disease for all infants January 5, 2023 2:00 AM - Globe NewsWire Sanofi (SAN:FP) (SNY) PT Raised to EUR110 at Stifel January 4, 2023 3:18 AM - StreetInsider Press Release: Availability of the Q4 2022 Memorandum for modelling purposes January 4, 2023 1:30 AM - Globe NewsWire JPMorgan Reinstates Sanofi (SAN:FP) (SNY) at Overweight January 3, 2023 1:28 AM - StreetInsider Sanofi (SAN:FP) (SNY) PT Raised to EUR113 at Baader Helvea December 29, 2022 3:45 AM - StreetInsider Press Release: Positive Dupixent® (dupilumab) Phase 3 results in adults and adolescents with eosinophilic esophagitis published in the New England Journal of Medicine December 21, 2022 5:30 PM - Globe NewsWire Positive Dupixent® (dupilumab) Phase 3 Results in Adults and Adolescents with Eosinophilic Esophagitis Published in the New England Journal of Medicine December 21, 2022 5:29 PM - PR NewsWire Sanofi (SNY) settles California Zantac case December 21, 2022 12:09 PM - StreetInsider Form 6-K Sanofi For: Dec 20 December 20, 2022 6:15 AM - SEC Filing Goldman Sachs Reinstates Sanofi (SAN:FP) (SNY) at Buy December 19, 2022 4:09 AM - StreetInsider Press Release: Sanofi and Innate Pharma expand collaboration for natural killer cell therapeutics in oncology December 19, 2022 1:00 AM - StreetInsider Sanofi and Innate Pharma Expand Collaboration for Natural Killer Cell Therapeutics in Oncology December 19, 2022 1:00 AM - BizWire Press Release: Sanofi and Innate Pharma expand collaboration for natural killer cell therapeutics in oncology December 19, 2022 1:00 AM - Globe NewsWire Regeneron (REGN), Sanofi (SNY) Announces Dupixent Recommended for EU Approval by the CHMP for the Treatment of Eosinophilic Esophagitis December 16, 2022 7:30 AM - StreetInsider Press Release: Dupixent® (dupilumab) recommended for EU approval by the CHMP for the treatment of eosinophilic esophagitis December 16, 2022 7:30 AM - Globe NewsWire Dupixent® (dupilumab) Recommended for EU Approval by the CHMP for the Treatment of Eosinophilic Esophagitis December 16, 2022 7:29 AM - PR NewsWire Regeneron (REGN) and Sanofi (SNY) Announce EU Approval of Dupixent for Prurigo Nodularis December 15, 2022 5:47 AM - StreetInsider Press Release: Dupixent® (dupilumab) approved by European Commission as the first and only targeted medicine indicated for prurigo nodularis December 15, 2022 1:00 AM - Globe NewsWire Dupixent® (dupilumab) Approved by European Commission as the First and Only Targeted Medicine Indicated for Prurigo Nodularis December 15, 2022 12:59 AM - PR NewsWire Sanofi (SAN:FP) (SNY) PT Raised to EUR97 at UBS December 14, 2022 5:22 AM - StreetInsider Morgan Stanley Resumes Sanofi (SAN:FP) (SNY) at Overweight December 13, 2022 2:15 AM - StreetInsider Sanofi shares rise after French drugmaker ditches Horizon deal talks December 12, 2022 5:19 AM - StreetInsider Amgen (AMGN) acquires Horizon (HZNP) for $26 billion as Sanofi (SNY) drops bid December 12, 2022 5:17 AM - StreetInsider European stocks weaken; caution ahead of central bank meetings December 12, 2022 4:36 AM - StreetInsider Amgen (AMGN) in advanced talks to acquire Horizon Therapeutics (HZNP) - WSJ December 11, 2022 9:07 PM - StreetInsider Press Release: Statement from Sanofi regarding Horizon Therapeutics plc (“Horizon”) December 11, 2022 1:21 PM - Globe NewsWire Sanofi (SNY) 30-day option implied volatility at 30 December 9, 2022 4:53 AM - StreetInsider European stocks mixed; recession concerns clash with China reopening December 7, 2022 4:12 AM - StreetInsider Stifel Reiterates Buy Rating on Sanofi (SAN:FP) (SNY) December 7, 2022 3:24 AM - StreetInsider GSK, Pfizer, Sanofi fend off thousands of U.S. lawsuits over alleged Zantac cancer link December 6, 2022 2:59 PM - StreetInsider GSK (GSK), Sanofi (SNY) Jump After US Court Win In Zantac Litigation - Bloomberg December 6, 2022 2:24 PM - StreetInsider Sanofi (SNY) gaining with GSK, up 3.4% December 6, 2022 2:05 PM - StreetInsider Global pharma giants partner Singapore researchers to boost innovation in biologics and vaccines manufacturing December 6, 2022 1:26 AM - StreetInsider Rumors Buzzing Around Wall Street Today December 5, 2022 5:22 PM - StreetInsider Horizon Therapeutics (HZNP) downticks as one of three bidders drops out December 5, 2022 9:38 AM - StreetInsider Form 6-K Sanofi For: Dec 02 December 2, 2022 10:41 AM - SEC Filing Horizon Therapeutics (HZNP) Adds to Gains as Two Potential Bidders Disclose All-Cash Deal December 2, 2022 10:07 AM - StreetInsider Sanofi (SNY) Said Any Offer for Horizon Therapeutics plc (HZNP) Would Be All Cash December 2, 2022 6:28 AM - StreetInsider Press Release: Statement from Sanofi regarding: rule 2.12 of the takeover rules December 2, 2022 1:55 AM - Globe NewsWire Midday movers: DoorDash, Workday, Hormel and more November 30, 2022 12:45 PM - StreetInsider Horizon Therapeutics seen worth up to $140/share in takeover November 30, 2022 8:12 AM - StreetInsider Sanofi (SNY) option IV flat November 30, 2022 5:58 AM - StreetInsider After-Hours Movers: Horizon Therapeutics Gains on Takeover Talks, CrowdStrike Sinks on EPS November 29, 2022 5:56 PM - StreetInsider 3 Rumors Pushing Around Stocks Today November 29, 2022 5:41 PM - StreetInsider Horizon Therapeutics (HZNP) jumps after confirming takeover talks with 3 parties November 29, 2022 5:23 PM - StreetInsider Horizon Therapeutics (HZNP) Confirms Talks on Takeover With Three Large Pharma Cos. November 29, 2022 4:26 PM - StreetInsider Form 6-K Sanofi For: Nov 21 November 21, 2022 10:05 AM - SEC Filing Press Release: European Commission approves Enjaymo® (sutimlimab) for treatment of hemolytic anemia in adult patients with cold agglutinin disease November 17, 2022 12:50 PM - Globe NewsWire Form 6-K Sanofi For: Nov 15 November 15, 2022 3:02 PM - SEC Filing Press Release: Dupixent® (dupilumab) recommended for EU approval by the CHMP for the treatment of prurigo nodularis November 11, 2022 7:00 AM - Globe NewsWire Dupixent® (dupilumab) Recommended for EU Approval by the CHMP for the Treatment of Prurigo Nodularis November 11, 2022 6:59 AM - PR NewsWire Form 6-K Sanofi For: Nov 10 November 10, 2022 2:01 PM - SEC Filing Sanofi (SNY) and GSK’s (GSK) next-generation COVID-19 booster vaccine VidPrevtyn® Beta approved by the European Commission November 10, 2022 10:39 AM - StreetInsider Press Release: Sanofi and GSK’s next-generation COVID-19 booster vaccine VidPrevtyn® Beta approved by the European Commission November 10, 2022 10:36 AM - Globe NewsWire Sanofi (SNY) and AstraZeneca (AZN) Announce EU Approval of Beyfortus November 4, 2022 5:37 AM - StreetInsider Press Release: European Commission grants first approval worldwide of Beyfortus® (nirsevimab) for prevention of RSV disease in infants November 4, 2022 3:00 AM - Globe NewsWire Full Article List